Doxycycline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: -PO Susceptible infections 200 mg on the first day, then 100 mg/day. Severe infections: 200 mg/day. Sexually transmitted diseases; Uncomplicated gonorrhoea 100 mg bid for 7 days. Epididymo-orchitis due to Chlamydia trachomatis or Neisseria gonorrhoeae 100 mg bid for 10 days. Syphilis 300 mg/day for at least 10 days. Relapsing fever and louse-borne typhus 100 or 200 mg as a single dose. Prophylaxis of scrub typhus 200 mg as a single dose. Chloroquine resistant falciparum malaria acute attack In combination with quinine: 200 mg/day for at least 7 days. Prophylaxis of malaria 100 mg/day. Treatment and postexposure prophylaxis of inhalation anthrax 100 mg bid for 60 days. Prophylaxis of traveller's diarrhoea 200 mg on the first day of travel, then 100 mg/day. Prophylaxis of leptospirosis 200 mg/week throughout the trip, then 200 mg on the last day of trip. Acne 50 mg/day for 6-12 weeks. Periodontitis 20 mg bid up to 3 months. IV Susceptible infections 200 mg on day 1 followed by 100-200 mg/day depending on the severity of infection. Topical/Cutaneous Periodontitis As 10% controlled-release subgingival preparation: Inject into the periodontal pocket, may be repeated 4 months after initial treatment.
Administration
May be taken with or without food. Take w/ a full glass of water & remain upright for at least 30 min. Take w/ food or milk if GI irritation occurs.
Contraindications
Hypersensitivity to doxycycline and other tetracycline congeners. Known or suspected achlorhydria (film-coated tab). Children <8 years (except for anthrax). Pregnancy and lactation. Concomitant use of methoxyflurane.
Special Precautions
Patient with coexisting venereal disease, myasthenia gravis, SLE; history or predisposition to oral candidosis (film-coated tab). Hepatic and renal impairment. Patient Counselling Avoid exposure to direct sunlight or UV light. Monitoring Parameters Before treatment, perform sensitivity testing. Monitor CBC, LFT and renal function.
Adverse Reactions
Significant: Microbial overgrowth including fungi, pseudomembranous colitis, oesophagitis, oesophageal ulceration, benign intracranial hypertension, discolouration of teeth, enamel hypoplasia, photosensitivity, exfoliative dermatitis, erythema multiforme, drug reaction with eosinophilia and systemic symptoms, Jarisch-Herxheimer reaction (if with spirochete infection); rarely, transient increases in LFT, porphyria. Blood and lymphatic system disorders: Haemolytic anaemia, neutropenia, eosinophilia, thrombocytopenia. Cardiac disorders: Tachycardia, pericarditis. Ear and labyrinth disorders: Tinnitus. Eye disorders: Blurred vision, diplopia, scotomata. Gastrointestinal disorders: Stomatitis, nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, pancreatitis. General disorders and administration site conditions: Peripheral oedema. Hepatobiliary disorders: Jaundice. Immune system disorders: Angioneurotic oedema, urticaria, serum sickness. Investigations: Brown/black discolouration of thyroid tissue, increased serum AST. Metabolism and nutrition disorders: Anorexia. Musculoskeletal and connective tissue disorders: Arthralgia, myalgia. Nervous system disorders: Headache. Reproductive system and breast disorders: Vaginitis. Respiratory, thoracic and mediastinal disorders: Dyspnoea. Skin and subcutaneous tissue disorders: Rashes, photo-onycholysis, skin hyperpigmentation. Vascular disorders: Hypotension.
Potentially Fatal: Anaphylactoid reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, Clostridium difficile-associated disease (CDAD), hepatotoxicity.
Drug Interactions
Risk of pseudotumour cerebri with isotretinoin. Risk of breakthrough bleeding with oral contraceptives. Prolonged prothrombin time with anticoagulants (e.g. warfarin). Decreased exposure with antacids containing Al, Ca or Mg, Zn, Fe salts, bismuth preparations, carbamazepine, phenobarbital, phenytoin and primidone. May increase the exposure of ciclosporin. May interfere with the bactericidal action of penicillin. Drugs that induce hepatic enzymes (e.g. rifampicin) may decrease the half-life of doxycycline.
ATC Classification
A01AB22 - doxycycline ; Belongs to the class of local antiinfective and antiseptic preparations. Used in the treatment of diseases of the mouth.
J01AA02 - doxycycline ; Belongs to the class of tetracyclines. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on doxycycline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in